NCT06894251Recruiting
Effect of LIMICOL®-NG on Plasma LDL-cholesterol Concentration in Subjects with Moderate Hypercholesterolemia
Source: ClinicalTrials.gov · Last updated 25 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to observe a decrease in plasma LDL cholesterol concentration of 10% (or 0.20g/L) in subjects with untreated moderate hypercholesterolemia after 3 months of consumption of the Limicol®-NG food supplement, compared with a historical placebo group
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- First submitted
- 11 Mar 2025
- Start date
- 10 Mar 2025
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- Institut Pasteur de Lille
- Diseases
- Familial hypercholesterolaemia
- NCT number
- NCT06894251
What you commit to
- Study type: Interventional
- Planned participants: 35
- From 10 Mar 2025 to the primary completion date, 30 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects receiving hypolipidemic or anti-dyslipidemic treatment (statin, ezetimibe, cholestyramine, fibrate, etc.)
- Subject requiring immediate treatment with statin
- Diabetic subjects treated or not with medication
- Whose state of health or concomitant treatments are judged by the principal investigator or a qualified co-investigator to be incompatible with the proper conduct of the clinical study.
Other illness
- Subjects suffering from a severe chronic condition deemed incompatible with the study by the investigator (serious digestive pathologies, renal failure, coronary pathology, immunodeficiency, heart failure, rhythm disorders, progressive tumor pathology, blood disease)
- Subject suffering from a severe eating disorder (anorexia, bulimia, binge eating disorder)
Other
- Subjects presenting triglyceridemia \> 4g/L (Friedewald)
- Subject requiring immediate dietary intervention or having fluctuating eating behavior
- Subjects with unstable treatment (for less than three months), or requiring the implementation of treatment during the study which, according to the investigator, could interfere with the evaluation of the study criteria (efficacy: LDL, TG, HDL, blood sugar, blood pressure, weight; safety: markers of liver, muscle or kidney function)
- Subjects who have consumed in the last 3 months food supplements or functional foods that could impact cholesterol or TG levels (phytosterol, phytostanol, red yeast rice, policosanols, beta-glucans at a dose greater than 3 g/day, probiotics)
- Pregnant woman or planning to become pregnant during the study period or breastfeeding
Who the study is looking for
- For women
- If pre-menopausal: effective non-estrogenic contraception established for at least 2 cycles, to be maintained during the study,
- If menopausal: without estrogenic Hormone Replacement Therapy (HRT)
- LDL cholesterol \>1.3 g/L (according to Friedewald calculation);
- Having stable eating habits, a level of physical activity and a weight for at least 3 months before the start of the study;
- Agreeing to maintain their lifestyle habits throughout the duration of the study;
- Agreeing to follow the constraints generated by the study;
- Having signed the informed consent form;
- Social security insured.
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NutrInvest - Institut Pasteur de Lille Coordinator of this site? Confirm its status | Lille | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.